Mereo BioPharma Group PLC (MREO)
| Market Cap | 141.55M |
| Revenue (ttm) | 50.30M |
| Net Income (ttm) | -37.13M |
| Shares Out | 116.98M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 509,224 |
| Open | 1.18 |
| Previous Close | 1.20 |
| Day's Range | 1.11 - 1.24 |
| 52-Week Range | 1.05 - 4.71 |
| Beta | 1.44 |
| Analysts | Strong Buy |
| Price Target | 9.30 (+668.7%) |
| Earnings Date | n/a |
About MREO
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197...
Analyst Forecast
According to 3 analysts, the average rating for MREO stock is "Strong Buy." The 12-month stock price forecast is 9.30, which is an increase of 668.72% from the latest price.
News
Mereo BioPharma's Alvelestat Shows Improvement In COVID-19 Severity
The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO) announced topline data from a Phase 1b/2 trial of alvelestat in hospitalized COVID-19 Respiratory Disease patie...
UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitaliz...
Alvelestat reported safe and well-tolerated in patients with COVID-19
5 Penny Stocks To Buy For Under $5 This Week
5 penny stocks to buy for under $5 right now. Are they worth the risk?
Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo's Alvelestat in Bronchiolitis Obliterans Syndrom...
LONDON and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and...
Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer
Mereo BioPharma Group plc (NASDAQ: MREO) reported interim data from ACTIVATE Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with Bristol Myers Squibb Co (NYSE: BMY) Opdivo (nivo...
Data from Investigator-sponsored Trial of Mereo BioPharma's alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Acc...
LONDON and REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and...
2 Growth Stocks That Could Deliver 1,000% Returns
These two low-priced biotech stocks could produce life-changing returns for early shareholders.
Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors
LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and...
Mereo's Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome
Mereo BioPharma Group plc (NASDAQ: MREO) has announced data from an interim analysis of an investigator-initiated study of alvelestat, in patients with Bronchiolitis Obliterans Syndrome (BOS), following...
Cancer Focus Fund To Finance Mereo's Ovarian Cancer Study With Etigilimab
Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc (NASDAQ: MREO), has entered into a funding agreement. The partners...
Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology an...
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta ---- Further Strengthened Management Team ---- OncXerna Global Licensing Agreement for Navicixizumab ---- Stre...
Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Und...
LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...
Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares
LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares
LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...
Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise
Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on ...
LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
LONDON and REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020
LONDON and REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference
LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regula...
LONDON and REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)
On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update
On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020